DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR
Citations Over TimeTop 10% of 2016 papers
Abstract
DNA methyltransferase DNMT3B is frequently overexpressed in tumor cells and plays important roles during the formation and progression of several cancer types. However, the specific signaling pathways controlled by DNMT3B in cancers, including melanoma, are poorly understood. Here, we report that DNMT3B plays a pro-tumorigenic role in human melanoma and that DNMT3B loss dramatically suppresses melanoma formation in the Braf/Pten mouse melanoma model. Loss of DNMT3B results in hypomethylation of the miR-196b promoter and increased miR-196b expression, which directly targets the mTORC2 component Rictor. Loss of RICTOR in turn prevents mTORC2 activation, which is critical for melanoma formation and growth. These findings establish Dnmt3b as a regulator of melanoma formation through its effect on mTORC2 signaling. Based on these results, DNMT3B is a potential therapeutic target in melanoma.
Related Papers
- → Current development of the second generation of mTOR inhibitors as anticancer agents(2011)113 cited
- → The functions of mTOR in ischemic diseases(2011)58 cited
- Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.(2010)
- → Control of Growth by the mTOR Pathway(2012)1 cited
- Structural and Functional Analysis of mTORB(2013)